Gilead to buy CV Therapeutics for $1.4 billion
March 12, 2009 at 08:57 AM EDT
Gilead Sciences agrees to acquire CV Therapeutics for $1.4 billion, marking just the latest in a recent flurry of drug-industry mergers. The acquisition premium works out to 25%.
